Potential of fumarate reductase as a novel therapeutic target in Helicobacter pylori infection

Bibliography

• WARREN JR, MARSHALL BJ: Unidentified curved bacilli on gastric epithelium in active chronic gastritis. Lancet (1983) 1:1273–1275.
   PubMed Web of Science ®Google Scholar
• ••First isolation of H pylorifrom the humanstomach.
   Google Scholar
• NIH consensus development panel on Helicabacter pylori in peptic ulcer disease. Helicabacter pylori in peptic ulcer disease. J Ain. Med. Assoc. (1994) 272:65–69.
   PubMed Web of Science ®Google Scholar
• FORMAN D, WEBB P, PARSONNET J: H pylori and gastric cancer. Lancet (1994) 34:243–244.
   Google Scholar
• PARSONNET J, HANSEN S, RODRIGUEZ L et al: Helicabacter pylori infection and gastric lymphoma. N Erigl. Med. (1994) 330:1267–1271.
   PubMed Web of Science ®Google Scholar
• TOMB JF, WHITE O, KERLAVAGE AR et al: The complete genome sequence of the gastric pathogen Helicabacter pylori. Nature (1997) 388:539–547.
   PubMed Web of Science ®Google Scholar
• •The first complete nucleotide sequence of the H pylori genome.
   Google Scholar
• ALM RA, LING LS, MOIR DT et al.: Genomic-sequence comparison of two unrelated isolates of the human gastric pathogen Helicabacter pylori. Nature (1999) 397:176–180.
   PubMed Web of Science ®Google Scholar
• •Discovery of the genetic basis for genomic variations among H pylori isolates.
   Google Scholar
• VAN HELLEMOND JJ, TIELENS AG: Expression and functional properties of fumarate reductase. Biachein. j (1994) 304:321–331.
   PubMed Web of Science ®Google Scholar
• •Excellent review on the molecular basis for the functioning of FRD.
   Google Scholar
• PITS ON SM, MENDZ GL, SRINIVASAN S, HAZELL SL: The tricarboxylic acid cycle of Helicabacter pylori. Eur. Biachein. (1999) 260:258–267.
   PubMed Web of Science ®Google Scholar
• •Proposal that H pylori has a noncyclic, branched TCA cycle.
   Google Scholar
• MARAIS A, MENDZ GL, HAZELL SL, MEGRAUD F: Metabolism and genetics of Helicobacter pylori: the genome era. ll/licrobial. Mal Biol. Rev (1999) 63:642–674.
   PubMed Web of Science ®Google Scholar
• •Detailed description of metabolite pathways that may operate in H pylorL
   Google Scholar
• DOIG E DE JONGE BL, ALM RA etal.: Helicabacter pylori physiology predicted from genomic comparison of two strains. ll/licrobial. Mal Biol. Rev. (1999) 63:675–707.
   PubMed Web of Science ®Google Scholar
• •Detailed description of metabolite pathways that may operate in H pylorL
   Google Scholar
• HOUBEN MH, VAN DER BEEK D, HENSEN EF, CRAEN AJ, RAUWS EA, TYTGAT GN: A systematic review of Helicabacter pylori eradication therapy - the impact of antimicrobial resistance on eradication rates. Aliment. Pharmacol. Ther. (1999) 13:1047–1055.
   PubMed Web of Science ®Google Scholar
• GRAHAM DY: Therapy of Helicabacter pylori: current status and issues. Gastroenterology (2000) 118\(Supp1.1):S2–58.
   Google Scholar
• VAN OIJEN AH, VERBEEK AL, JANSEN JB, DE BOER WA: Review article: treatment of Helicabacter pylori infection with ranitidine bismuth citrate or proton pump inhibitor-based triple therapies. Aliment. Pharmacy]. Ther. (2000) 14:991–999.
   PubMed Web of Science ®Google Scholar
• DE BOER WA, TYTGAT GN: Regular review: treatment of Helicabacter pylori infection. Br Med .j (2000) 320:31–34.
   PubMed Web of Science ®Google Scholar
• OSATO MS, REDDY SG, PIERGIES AA, BOCHENEK WJ, TESTA RT, GRAHAM DY: Comparative efficacy of new investigational agents against Helicabacter pylori Ailment. Pharmacy]. Then. (2001) 15:487–492.
   Web of Science ®Google Scholar
• WANG G, WILSON TJ, JIANG Q, TAYLOR DE: Spontaneous mutations that confer antibiotic resistance in Helicabacter pylori Antimicrob. Agents Cheinother (2001) 45:727–733.
   PubMed Web of Science ®Google Scholar
• TAYLOR DE, GE Z, PURYCH D, LO T, HIRATSUKA K: Cloning and sequence analysis of two copies of a 23S rRNA gene from Helicabacter pylori and association of clarithromycin resistance with 23S rRNA mutations. Aritimicrob. Agents Chemother. (1997) 41:2621–2628.
   PubMed Web of Science ®Google Scholar
• WANG G, JIANG Q, TAYLOR DE: Genotypic characterization of clarithromycin -resistant and -susceptible Helicabacter pylori strains from the same patient demonstrates existence of two unrelated isolates. J. Clin. Microbial (1998) 36:2730–2731.
   PubMed Web of Science ®Google Scholar
• WONG BC, WANG WH, BERG DE et al.: High prevalence of mixed infections by Helicabacter pylori in Hong Kong: metronidazole sensitivity and overall genotype. Aliment. Pharmacy]. Ther (2001) 15:493–503.
   PubMed Web of Science ®Google Scholar
• JEONG JY, MUKHOPADHYAY AK, DAILIDIENE D et al: Sequential inactivation of rdxA (HP0954) and frxA (HP0642) nitroreductase genes causes moderate and high-level metronidazole resistance in HelicobacterBacterial (2000) 182:5082–5090.
   Google Scholar
• KWON DH, LEE M, KIM JJ et al.: Furazolidone- and nitrofurantoin-resistant Helicobacter pylori: prevalence and role of genes involved in metronidazole resistance. Ant/micron. Agents. Cliemotlier. (2001) 45:306–308.
   PubMed Web of Science ®Google Scholar
• FAKHERI H, MALEKZADEH R, MERAT S et al.: Clarithromycin versus furazolidone in quadruple therapy regimens for the treatment of Helicobacter pylori in a population with a high metronidazole resistance rate. Ailment. Pharmacy]. Ther. (2001)15:411–416.
   PubMed Web of Science ®Google Scholar
• BELL GD, POWELL K, BURRIDGE SM et al.: Experience with anti-Helicobacter pylori eradication therapy: side effects and the importance of testing the pre-treatment bacterial isolate for metronidazole resistance. Aliment. Pharmacy]. Ther. (1992) 6:427–435.
   PubMed Web of Science ®Google Scholar
• GRAHAM DY: Antibiotic resistance in Helicobacter pylori: implications for therapy. Gastroenterology (1998) 115:1272–1277.
   PubMed Web of Science ®Google Scholar
• DEL GIUDICE G, COVACCI A, TELFORD JL, MONTECUCCO C, RAPPUOLI R: The design of vaccines against Helicobacter pylori and their development. Ann. Rev Immune]. (2001) 19:523–563.
   PubMed Web of Science ®Google Scholar
• ••Excellent review on the development ofvaccines against H pylori infection.
   Google Scholar
• GOMEZ-DUARTE OG, LUCAS B, YAN ZX, PANTHEL K, HAAS R, MEYER TF: Protection of mice against gastric colonization by Helicobacter pyloriby single oral dose immunization with attenuated Salmonella nphimurium producing urease subunits A and B. Vaccine (1998) 16:460–471.
   PubMed Web of Science ®Google Scholar
• CORTHESY-THEULAZ IE, HOPKINS S, BACHMANN D et al: Mice are protected from Helicobacter pylori infection by nasal immunization with attenuated Salmonella nphimurium phoPc expressing urease A and B subunits. Infect. Immun. (1998) 66:581–586.
   PubMed Web of Science ®Google Scholar
• MICHETTI P, KREISS C, KOTLOFF et al: Oral immunization with urease and Escherichia coil heat-labile enterotoxin is safe and immunogenic in Helicobacter pylori-inTected adults. Gastroenterology (1999) 116:804–812.
   PubMed Web of Science ®Google Scholar
• DIPETRILLO MD, TIBBETTS T, KLEANTHOUS H, KILLEEN KP, HOHMANN EL: Safety and immunogenicity of phoP/phoQ-deleted Salmonella nphi expressing Helicobacter py/oriurease in adult volunteers. Vaccine (1999) 18:449–459.
   PubMed Web of Science ®Google Scholar
• KOTLOFF KL, SZTEIN MB, WASSERMAN SS, LOSONSKY GA, DILORENZO SC, WALKER RI: Safety and immunogenicity of oral inactivated whole-cell Helicobacter pylori vaccine with adjuvant among volunteers with or without subclinical infection. Infect. Immun. (2001) 69:3581–3590.
   PubMed Web of Science ®Google Scholar
• GE Z, JIANG Q, KALISIAK MS, TAYLOR DE: Cloning and functional characterization of Helicabacter pylori fumarate reductase operon comprising three structural genes coding for subunits C, A and B. Gene (1997) 204:227–234.
   PubMed Web of Science ®Google Scholar
• •Sequence and functional analysis of H pylori FRD, demonstrating that this enzyme is not essential for its growth in vitro.
   Google Scholar
• KORTNER C, LAUTERBACH F, TRIPIER D, UNDEN G, KROGER A: Wolinella succinagenes fumarate reductase contains a dihaem cytochrome b. Mal Microbial (1990) 4:855–860.
   PubMed Web of Science ®Google Scholar
• LAUTERBACH F, KORTNER C, ALBRACHT SP, UNDEN G, KROGER A: The fumarate reductase operon of Walinella succinagenes. Sequence and expression of the frdA and fi-dB genes. Arch. Microbial (1990) 154:386–393.
   Google Scholar
• PARKHILL J, WREN BW, MUNGALL K et al.: The genome sequence of the food-borne pathogen Campylobacter ft:jun/reveals hypervariable sequences. Nature (2000) 403:665–668.
   PubMed Web of Science ®Google Scholar
• HAGERHÄLL C, HDERSTEDT L: A structural model for the membrane-integral domain of succinate:quinone oxideoreductases. FEBS Lett. (1996) 389:25–31.
   PubMed Web of Science ®Google Scholar
• GORDON EH, PEALING SL, CHAPMAN SK, WARD FB, REID GA: Physiological function and regulation of flavocytochrome c3, the soluble fumarate reductase from Shewartella putrefaciens NCIMB 400. Microbiology (1998) 144:937–945.
   PubMed Web of Science ®Google Scholar
• LANCASTER CR, KROGER A, AUER M, MICHEL H: Structure of fumarate reductase from Walinella succinagenes at 2.2 A resolution. Nature (1999) 402:377–385.
   PubMed Web of Science ®Google Scholar
• •Crystal structures of W succinogenes FRD subunits similar to those in H pylorL
   Google Scholar
• IVERSON TM, LUNA-CHAVEZ C, CECCHINI G, REES DC: Structure of the Escherichia coil fumarate reductase respiratory complex. Science (1999) 284:1961–1966.
   PubMed Web of Science ®Google Scholar
• KOWAL AT, WERTH MT, MANODORI A et al.: Effect of cysteine to serine mutations on the properties of the (4Fe-45) center in Escherichia coli fumarate reductase. Biochemistry (1995) 34:12284–12293.
   PubMed Web of Science ®Google Scholar
• SCHRODER I, GUNSALUS RP, ACKRELL BA, COCHRAN B, CECCHINI G: Identification of active site residues of Escherichia coil fumarate reductase by site-directed mutagenesis. J. Biol. Chem. (1991) 266:13572–13579.
   PubMed Web of Science ®Google Scholar
• LANCASTER CR, GORSS R, HAAS A et al: Essential role of Glu-C66 for menaquinol oxidation indicates transmembrane electrochemical potential generation by Walinella succinagenes fumarate reductase. Proc. Natl. Acad. Sri. USA (2000) 97:13051–13056.
   PubMed Web of Science ®Google Scholar
• SIMON J, GROSS R, RINGEL M, SCHMIDT E, KROGER A: Deletion and site-directed mutagenesis of the Walinella succinagenes fumarate reductase operon. Eur. Biochem. (1998) 251:418–426.
   PubMedGoogle Scholar
• MENDZ GL, HAZELL SL: Fumarate catabolism in Helicobacter pylori. Biochem. Mal Biol. Int. (1993) 31:325–332.
   PubMedGoogle Scholar
• MENDZ GL, HAZELL SL, SRINIVASAN S: Fumarate reductase: a target for therapeutic intervention against Helicobacter pylori. Arch. Biochem. Biophys. (1995) 321:153–159.
   PubMed Web of Science ®Google Scholar
• ••Demonstration of H pylori FRD as apotential therapeutic target.
   Google Scholar
• BIRKHOLZ S, KNIPP U, LEMMA E, KROGER A, OPFERKUCH W: Fumarate reductase of Helicobacter pylori - an immunogenic protein. j Med. Microbial (1994) 41:56–62.
   PubMed Web of Science ®Google Scholar
• •Identification of H pylori FrdA as an immunogenic protein.
   Google Scholar
• EIGLMEIER K, HONORE N, IUCHI S, LIN EC, COLE ST: Molecular genetic analysis of FNR-dependent promoters. Mal Microbial (1989) 3:869–878.
   PubMed Web of Science ®Google Scholar
• HOFFMAN PS, GOODWIN A, JOHNSEN J, MAGEE K, VELDHUYZEN VAN ZANTEN SJ:
   Google Scholar
• •• Metabolic activities of metronidazole-sensitive and -resistant strains of Helicobacter pylori: repression of pyruvate oxidoreductase and expression of isocitrate lyase activity correlate with resistance. Bacterial. (1996) 178:4822–4829.
   Google Scholar
• CORTHESY-THEULAZ IE, BERGONZELLI GE, HENRY H et al.: Cloning and characterization of Helicobacter pylori succinyl CoA:acetoacetate CoA-transferase, a novel prokaryotic member of the CoA-transferase family. I Biol. Chem. (1997) 272:25659–2567.
   Web of Science ®Google Scholar
• HUGHES NJ, CLAYTON CL, CHALK PA, KELLY DJ: Helicobacter pylori parCDAB and oarDABC genes encode distinct pyruvate:flavodoxin and 2-oxoglutarate:acceptor oxidoreductases which mediate electron transport to NAEP. J. Bacterial. (1998) 180:1119–1128.
   PubMed Web of Science ®Google Scholar
• KATHER B, STINGL K, VAN DER REST ME, ALTENDORF K, MOLENAAR D: Another unusual type of citric acid cycle enzyme in Helicobacter pylori: the malate:quinone oxidoreductase. Bacterial. (2000) 182:3204–3209.
   PubMed Web of Science ®Google Scholar
• •Possible existence of the cyclic TCA in H pylori
   Google Scholar
• CHEN M, ANDERSEN LP, ZHAI L, KHARAZMI A: Characterization of the respiratory chain of Helicobacter pylori. FEMS Immune]. Med. Microbial. (1999) 24:169–74.
   PubMedGoogle Scholar
• MAKLASHINA E, BERTHOLD DA, CECCHINI G: Anaerobic expression of Escherichia coil succinate dehydrogenase: functional replacement of fumarate reductase in the respiratory chain during anaerobic growth. j Bacterial. (1998) 180:5989–5996.
   PubMed Web of Science ®Google Scholar
• MENDZ GL, MEEK DJ, HAZELL SL: Characterization of fumarate transport in Helicobacter pylori. I Membr. Biol. (1998) 165:65–76.
   PubMed Web of Science ®Google Scholar
• GE Z, FENG Y, DANGLER CA, XU S, TAYLOR NS, FOX JG: Fumarate reductase is essential for Helicobacter pylori colonization of the mouse stomach. Microb. Pathog. (2000) 29:279–287.
   PubMed Web of Science ®Google Scholar
• ••Demonstration of H pylori FRD as anessential enzyme for its colonisation in the mouse model.
   Google Scholar
• GE Z, HIRATSUKA K, TAYLOR DE: Nucleotide sequence and mutational analysis indicate that two Helicobacter pylori genes encode a P-type ATPase and a cation-binding protein associated with copper transport. Mal. Microbial. (1995) 15:97–106.
   PubMed Web of Science ®Google Scholar
• CONDON C, WEINER JH: Fumarate reductase of Escherichia coil: an investigation of function and assembly using in vivo complementation. Mal Microbial. (1988) 2:43–52.
   PubMed Web of Science ®Google Scholar
• SIMON J, GROSS R, RINGEL M, SCHMIDT E, KROGER A: Deletion and site-directed mutagenesis of the Walinella succinageries fumarate reductase operon. Eur. Biochem. (1998) 251:418–426.
   PubMedGoogle Scholar
• BHATTACHARYYA S, GE Z, KRISHNAMURTHY P, CHAMBERS TJ, PHADNIS SH, FOX JG: Helicobacter pylori requires fumarate reductase for acid resistance. Castraeritalogy (2001) 120\(Supp1.1):A–655.
   Google Scholar
• •The finding that H pylori FRD plays a crucial role in acid resistance.
   Google Scholar
• VANDEN BOSSCHE H: Pharmacology of anthelmintics. In: Handbook of Experimental Pharmacology (Volume 77). Vanden Bossche H, Tienpont D, Janssens PG (Eds), Springger-Verlag, Berlin, Germany (1985):125–181.
   Google Scholar
• COLES GC: The biochemical mode of action of some modern anthelmintics. Pestic. Sci. (1977) 8:536–543.
   Google Scholar
• FRIEDMAN PA, PLATZER EG: Interaction of anthelmintic benzimidazoles and benzimidazole derivatives with bovine brain tubulin. Biochim. Biophys. Acta. (1978) 544:605–614.
   PubMed Web of Science ®Google Scholar
• IRELAND CM, GULL K, GUTTERIDGE WE, POGSON CI: The interaction of benzimidazole carbamates with mammalian microtobule protein. Biochem. Parmacal (1979) 28:2680–2682.
   PubMed Web of Science ®Google Scholar
• VANDEN BOSSCHE H, ROCHETTE F, HORIG C: Mebendazole and related anthelmintics. In: Advances in Pharmacology and Chemotherapy (Volume 19). Garattini S, Goldin A, Hawking F, Kopin IJ (Eds), Academic Press, New York, USA (1982):67–128.
   Google Scholar